Axsome Therapeutics (AXSM) Leases (2022 - 2025)
Axsome Therapeutics (AXSM) has disclosed Leases for 4 consecutive years, with $20.9 million as the latest value for Q4 2025.
- Quarterly Leases rose 287.48% to $20.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.9 million through Dec 2025, up 287.48% year-over-year, with the annual reading at $20.9 million for FY2025, 287.48% up from the prior year.
- Leases hit $20.9 million in Q4 2025 for Axsome Therapeutics, down from $21.7 million in the prior quarter.
- In the past five years, Leases ranged from a high of $23.9 million in Q1 2025 to a low of $106000.0 in Q1 2023.
- Historically, Leases has averaged $8.5 million across 4 years, with a median of $6.2 million in 2024.
- Biggest five-year swings in Leases: plummeted 88.8% in 2023 and later soared 5948.11% in 2024.
- Year by year, Leases stood at $420000.0 in 2022, then surged by 1512.38% to $6.8 million in 2023, then fell by 20.51% to $5.4 million in 2024, then surged by 287.48% to $20.9 million in 2025.
- Business Quant data shows Leases for AXSM at $20.9 million in Q4 2025, $21.7 million in Q3 2025, and $22.5 million in Q2 2025.